SynthesisInfection2018
Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.
Synthesis in Infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pulmonary Artery Pseudoaneurysm in COVID-19-Associated Pulmonary Mucormycosis: Case Series and Systematic Review of the Literature.Mycopathologia · 2022Pooled it
- Brazilian task force for the management of mucormycosis.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- Pulmonary mucormycosis: outcomes by treatment modality and underlying comorbidity.The Annals of thoracic surgery · 2026Article
- Clinical characteristics and risk factors for mortality in pulmonary mucormycosis among patients with non-hematologic malignancies.BMC pulmonary medicine · 2026Article
- Pulmonary artery floating sign: a novel predictor of fatal haemoptysis in pulmonary mucormycosis and its early intervention strategy.BMJ open respiratory research · 2026Article
- Real-World Outcomes of Amphotericin B Colloidal Dispersion as Salvage Therapy for Invasive Fungal Disease.Drug design, development and therapy · 2026Article
- Bronchoscopic local instillation of amphotericin B deoxycholate as adjunctive therapy for pulmonary mucormycosis with inadequate response to posaconazole: a retrospective case series.Frontiers in medicine · 2026Article
- Management of mould pneumonia in resource-limited settings in Asia: A Delphi-based consensus statement by the Asia Fungal Working Group.Medical mycology · 2025Article
- Successful Management of Refractory Pulmonary Mucormycosis Using Intracavitary Amphotericin B: A Case Report and Literature Review.The American journal of case reports · 2025Review
- Hematological diseases-related mucormycosis: A retrospective single center study.PLoS neglected tropical diseases · 2025Article
- Diagnosis, clinical features, and mortality risk factors in a Chinese cohort with pulmonary mucormycosis.PloS one · 2025Article
- Comparative Prognosis of Fungal Balls Versus Invasive Pulmonary Mucormycosis.Infection and drug resistance · 2025Article
- A Systematic Review of the Therapeutic Outcome of Mucormycosis.Open forum infectious diseases · 2024Review
- Clinical features of pediatric mucormycosis: role of metagenomic next generation sequencing in diagnosis.Frontiers in cellular and infection microbiology · 2024Article
- Fatal Tracheal and Bronchial Destruction Due to Pulmonary Mucormycosis in a 20-Year-Old with Diabetic Ketoacidosis.Infection and drug resistance · 2024Article
- Very severe aplastic anemia in a child with pulmonary mucormycosis: a case report.Frontiers in pediatrics · 2024Article
- Pulmonary Mucormycosis Involving the Left Main Bronchus and the Pulmonary Artery.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2023Article
- Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies.Journal of fungi (Basel, Switzerland) · 2023Review
- Epidemiology of Mucormycosis in Greece; Results from a Nationwide Prospective Survey and Published Case Reports.Journal of fungi (Basel, Switzerland) · 2023Article
- Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.Environmental science and pollution research international · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLittle is known about risk factors for the outcome of pulmonary mucormycosis. We summarized characteristics of this rare disease, and systemically explored risk factors for the outcome.
methodsNinety-two patients with pulmonary mucormycosis, including 12 patients at Peking Union Medical College Hospital and 80 patients published in 62 articles between 2006 and 2016, were retrospectively analyzed.
resultsThe median age was 47.5 years, and the male to female ratio was 2.8:1. Hematological disorders, diabetes mellitus, renal insufficiency and organ transplantation were main underlying conditions. Twelve percent of patients had no underlying diseases. A predilection for involvement of upper lobes was noted, and thick-walled cavity was described in 37.0% of patients on chest computed tomography. Most of the patients were diagnosed by microscopic analysis (95.7%), mainly histopathology; and only a minority were diagnosed by culture of sterile materials (28.3%). The overall mortality rate was 30.4%. Four independent determinants were associated with a better prognosis: hemoptysis (adjusted OR 7.910; 95% CI 1.411-44.342), chronic onset (adjusted OR 25.269, 95% CI 1.654-385.993), treated with medicine (adjusted OR 53.896, 95% CI 3.072-945.561), and treated with surgery (adjusted OR 5.983, 95% CI 1.497-23.918).
conclusionsPulmonary mucormycosis is a rare infection with a high mortality. Invasive approach for histopathology and culture are crucial for a definite diagnosis. Acute onset patients had a poorer prognosis, and early treatment with antifungal therapy is imperative. Surgical approach is recommended in appropriate patients for a better outcome.
Indexed as
Identifiers
29748841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.